 Brian Freed
Concepts (523)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HLA-DRB1 Chains | 8 | 2025 | 111 | 1.680 |
Why?
| | T-Lymphocytes | 22 | 2025 | 2045 | 1.350 |
Why?
| | Epitopes | 4 | 2016 | 491 | 1.170 |
Why?
| | HLA Antigens | 9 | 2024 | 227 | 0.890 |
Why?
| | Genetic Predisposition to Disease | 6 | 2016 | 2411 | 0.850 |
Why?
| | Lymphocyte Activation | 19 | 2006 | 1143 | 0.830 |
Why?
| | Arthritis, Rheumatoid | 4 | 2025 | 1171 | 0.810 |
Why?
| | Interleukin-2 | 16 | 2005 | 447 | 0.740 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2021 | 1701 | 0.680 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2022 | 125 | 0.680 |
Why?
| | Hydroquinones | 6 | 2003 | 29 | 0.670 |
Why?
| | Kidney Transplantation | 20 | 2019 | 702 | 0.660 |
Why?
| | Back Pain | 1 | 2021 | 52 | 0.640 |
Why?
| | HLA-B Antigens | 3 | 2024 | 57 | 0.630 |
Why?
| | HLA-DR Antigens | 5 | 2020 | 219 | 0.580 |
Why?
| | Alleles | 8 | 2025 | 883 | 0.550 |
Why?
| | Tars | 3 | 2006 | 5 | 0.540 |
Why?
| | Graft Rejection | 14 | 2019 | 538 | 0.540 |
Why?
| | Acrolein | 2 | 2007 | 22 | 0.490 |
Why?
| | Immunosuppressive Agents | 13 | 2017 | 844 | 0.480 |
Why?
| | Vimentin | 2 | 2016 | 54 | 0.470 |
Why?
| | Cyclosporins | 11 | 1991 | 70 | 0.460 |
Why?
| | Peptides, Cyclic | 2 | 2016 | 276 | 0.420 |
Why?
| | Catechols | 4 | 2003 | 15 | 0.410 |
Why?
| | Histocompatibility Antigens Class I | 3 | 2022 | 208 | 0.400 |
Why?
| | Peptides | 2 | 2016 | 1002 | 0.390 |
Why?
| | Transplantation, Haploidentical | 2 | 2024 | 23 | 0.390 |
Why?
| | Tissue Donors | 6 | 2018 | 423 | 0.380 |
Why?
| | Histocompatibility Antigens Class II | 5 | 2022 | 366 | 0.370 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2020 | 273 | 0.360 |
Why?
| | Fetal Blood | 6 | 2024 | 340 | 0.360 |
Why?
| | Smoking | 5 | 2011 | 1557 | 0.350 |
Why?
| | Cord Blood Stem Cell Transplantation | 5 | 2016 | 103 | 0.350 |
Why?
| | DNA | 7 | 2007 | 1430 | 0.350 |
Why?
| | Immune Tolerance | 4 | 2025 | 384 | 0.350 |
Why?
| | Smoke | 5 | 2007 | 152 | 0.340 |
Why?
| | B-Lymphocytes | 7 | 2021 | 890 | 0.340 |
Why?
| | Double-Blind Method | 2 | 2024 | 2030 | 0.330 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 5 | 2013 | 858 | 0.330 |
Why?
| | Humans | 93 | 2024 | 144857 | 0.320 |
Why?
| | Ribonucleotide Reductases | 2 | 2000 | 29 | 0.300 |
Why?
| | Graft Survival | 9 | 2017 | 525 | 0.300 |
Why?
| | Arachis | 1 | 2010 | 108 | 0.300 |
Why?
| | Immunoglobulin E | 1 | 2010 | 319 | 0.290 |
Why?
| | Immunoglobulin G | 4 | 2013 | 899 | 0.280 |
Why?
| | Peanut Hypersensitivity | 1 | 2010 | 143 | 0.280 |
Why?
| | Cells, Cultured | 11 | 2019 | 4177 | 0.270 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2007 | 23 | 0.260 |
Why?
| | Lymphocytes | 3 | 2013 | 396 | 0.260 |
Why?
| | Isoantibodies | 3 | 2017 | 57 | 0.260 |
Why?
| | Disease Models, Animal | 5 | 2021 | 4605 | 0.250 |
Why?
| | Plants, Toxic | 3 | 2000 | 18 | 0.240 |
Why?
| | CD4-Positive T-Lymphocytes | 5 | 2016 | 1147 | 0.230 |
Why?
| | Immune System | 2 | 2021 | 182 | 0.230 |
Why?
| | Histocompatibility Testing | 7 | 2019 | 121 | 0.230 |
Why?
| | Flow Cytometry | 5 | 2016 | 1193 | 0.220 |
Why?
| | Tuberculosis | 2 | 2023 | 289 | 0.220 |
Why?
| | Enzyme Inhibitors | 2 | 2000 | 832 | 0.220 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2006 | 90 | 0.220 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2006 | 80 | 0.220 |
Why?
| | Mycobacterium tuberculosis | 2 | 2023 | 335 | 0.220 |
Why?
| | Ethylmaleimide | 3 | 1991 | 18 | 0.220 |
Why?
| | Mental Disorders | 1 | 2014 | 1137 | 0.220 |
Why?
| | Antibodies | 3 | 2019 | 402 | 0.220 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2024 | 681 | 0.220 |
Why?
| | Haplotypes | 3 | 2014 | 491 | 0.210 |
Why?
| | Ganciclovir | 4 | 1997 | 53 | 0.210 |
Why?
| | Cell Line | 10 | 2016 | 2911 | 0.200 |
Why?
| | Cytomegalovirus Infections | 5 | 1997 | 207 | 0.200 |
Why?
| | Gene Frequency | 3 | 2019 | 485 | 0.200 |
Why?
| | Islets of Langerhans | 3 | 1994 | 835 | 0.190 |
Why?
| | Diabetes Mellitus, Type 1 | 5 | 2014 | 3854 | 0.190 |
Why?
| | Glutamic Acid | 1 | 2025 | 252 | 0.190 |
Why?
| | HLA-A Antigens | 1 | 2022 | 54 | 0.190 |
Why?
| | HLA-C Antigens | 1 | 2022 | 38 | 0.180 |
Why?
| | Interferon-gamma | 3 | 2005 | 792 | 0.180 |
Why?
| | Collagen | 1 | 2025 | 467 | 0.180 |
Why?
| | Cigarette Smoking | 1 | 2023 | 104 | 0.180 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2005 | 1225 | 0.180 |
Why?
| | Histocompatibility Antigens | 1 | 2022 | 103 | 0.180 |
Why?
| | Cyclosporine | 5 | 1998 | 264 | 0.170 |
Why?
| | Protein Binding | 3 | 2016 | 2276 | 0.170 |
Why?
| | In Vitro Techniques | 9 | 2005 | 1057 | 0.170 |
Why?
| | Receptors, KIR | 2 | 2022 | 110 | 0.170 |
Why?
| | Enoxaparin | 1 | 2022 | 68 | 0.170 |
Why?
| | Central Tolerance | 1 | 2021 | 10 | 0.170 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2021 | 41 | 0.170 |
Why?
| | DNA-Binding Proteins | 2 | 2011 | 1495 | 0.170 |
Why?
| | Transplantation, Homologous | 9 | 2019 | 414 | 0.170 |
Why?
| | Receptors, CXCR4 | 1 | 2021 | 91 | 0.160 |
Why?
| | HLA-DRB4 Chains | 1 | 2020 | 6 | 0.160 |
Why?
| | Heterografts | 1 | 2021 | 145 | 0.160 |
Why?
| | Gene Expression Regulation | 3 | 2016 | 2633 | 0.160 |
Why?
| | Receptors, Interleukin-2 | 5 | 2003 | 64 | 0.160 |
Why?
| | Evolution, Molecular | 1 | 2024 | 514 | 0.160 |
Why?
| | Brain Ischemia | 1 | 2024 | 356 | 0.160 |
Why?
| | Mice | 18 | 2025 | 18549 | 0.160 |
Why?
| | Cell Division | 4 | 1997 | 780 | 0.160 |
Why?
| | Nickel | 1 | 2020 | 64 | 0.160 |
Why?
| | Trace Elements | 1 | 2020 | 52 | 0.150 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2020 | 199 | 0.150 |
Why?
| | Bias | 1 | 2021 | 205 | 0.150 |
Why?
| | Receptors, Antigen, B-Cell | 2 | 2021 | 135 | 0.150 |
Why?
| | alpha 1-Antitrypsin | 1 | 2020 | 104 | 0.150 |
Why?
| | Transcription Factors | 2 | 2005 | 1741 | 0.150 |
Why?
| | Pulmonary Alveolar Proteinosis | 1 | 2019 | 16 | 0.150 |
Why?
| | Cell Cycle Proteins | 1 | 2003 | 636 | 0.150 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2020 | 64 | 0.150 |
Why?
| | Immunotherapy | 2 | 2021 | 672 | 0.140 |
Why?
| | Adrenocortical Carcinoma | 1 | 2020 | 67 | 0.140 |
Why?
| | Vascular System Injuries | 1 | 2019 | 80 | 0.140 |
Why?
| | Unrelated Donors | 2 | 2024 | 38 | 0.140 |
Why?
| | Animals | 26 | 2025 | 38331 | 0.140 |
Why?
| | Tacrolimus | 2 | 2017 | 197 | 0.140 |
Why?
| | Tumor Microenvironment | 2 | 2020 | 743 | 0.140 |
Why?
| | Insulin | 3 | 1994 | 2511 | 0.140 |
Why?
| | HEK293 Cells | 2 | 2022 | 752 | 0.140 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 1 | 2018 | 35 | 0.140 |
Why?
| | Transcription, Genetic | 2 | 2003 | 1506 | 0.130 |
Why?
| | Herpesvirus 4, Human | 1 | 2018 | 173 | 0.130 |
Why?
| | Cell Transplantation | 1 | 1997 | 39 | 0.130 |
Why?
| | Hydrogen Peroxide | 3 | 1988 | 340 | 0.130 |
Why?
| | Donor Selection | 1 | 2018 | 79 | 0.130 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2018 | 97 | 0.130 |
Why?
| | Antiviral Agents | 3 | 2020 | 749 | 0.130 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2019 | 219 | 0.130 |
Why?
| | Hypersensitivity | 1 | 2020 | 266 | 0.130 |
Why?
| | Proinsulin | 1 | 1997 | 52 | 0.130 |
Why?
| | Mutagenesis, Site-Directed | 2 | 2016 | 379 | 0.130 |
Why?
| | Amino Acid Sequence | 4 | 2016 | 2149 | 0.130 |
Why?
| | Benzoquinones | 1 | 1997 | 47 | 0.120 |
Why?
| | Mice, Inbred BALB C | 5 | 2021 | 1272 | 0.120 |
Why?
| | Transplantation Conditioning | 1 | 2018 | 190 | 0.120 |
Why?
| | Carcinogenesis | 1 | 2018 | 231 | 0.120 |
Why?
| | Complement System Proteins | 1 | 2019 | 317 | 0.120 |
Why?
| | Interleukin-1 | 1 | 2000 | 962 | 0.120 |
Why?
| | Phosphopyruvate Hydratase | 1 | 2016 | 26 | 0.120 |
Why?
| | Genetic Variation | 2 | 2015 | 991 | 0.120 |
Why?
| | HLA-DQ beta-Chains | 1 | 2016 | 59 | 0.120 |
Why?
| | Dextrans | 1 | 2016 | 86 | 0.120 |
Why?
| | Collagen Type II | 1 | 2016 | 54 | 0.120 |
Why?
| | Autoantibodies | 4 | 2021 | 1498 | 0.120 |
Why?
| | Cytotoxicity, Immunologic | 3 | 2012 | 227 | 0.120 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 194 | 0.120 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2019 | 220 | 0.120 |
Why?
| | Female | 29 | 2024 | 78217 | 0.120 |
Why?
| | Genotype | 3 | 2022 | 1841 | 0.110 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2016 | 392 | 0.110 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2022 | 1147 | 0.110 |
Why?
| | Adult | 19 | 2024 | 40438 | 0.110 |
Why?
| | Resting Phase, Cell Cycle | 2 | 2006 | 16 | 0.110 |
Why?
| | Protein Kinase C | 1 | 1996 | 253 | 0.110 |
Why?
| | Retrospective Studies | 10 | 2024 | 16937 | 0.110 |
Why?
| | Genetic Therapy | 1 | 1997 | 324 | 0.110 |
Why?
| | Methylprednisolone | 3 | 1991 | 63 | 0.110 |
Why?
| | Tobacco Smoke Pollution | 1 | 1997 | 237 | 0.110 |
Why?
| | Stroke | 1 | 2024 | 1227 | 0.110 |
Why?
| | Autoimmune Diseases | 1 | 2019 | 464 | 0.110 |
Why?
| | Clonal Anergy | 1 | 1994 | 55 | 0.110 |
Why?
| | G1 Phase | 2 | 2006 | 78 | 0.110 |
Why?
| | Kidney Failure, Chronic | 2 | 2017 | 600 | 0.110 |
Why?
| | Autoimmunity | 2 | 2021 | 927 | 0.100 |
Why?
| | Immunoglobulin Isotypes | 1 | 2013 | 37 | 0.100 |
Why?
| | Tumor Cells, Cultured | 4 | 2020 | 944 | 0.100 |
Why?
| | Lymphocyte Culture Test, Mixed | 7 | 1996 | 51 | 0.100 |
Why?
| | Sequence Analysis, RNA | 1 | 2016 | 452 | 0.100 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 988 | 0.100 |
Why?
| | Endothelial Cells | 1 | 2019 | 874 | 0.100 |
Why?
| | Hypoxanthine Phosphoribosyltransferase | 1 | 2013 | 25 | 0.100 |
Why?
| | C-Reactive Protein | 2 | 1987 | 419 | 0.100 |
Why?
| | Radioimmunoassay | 5 | 1990 | 167 | 0.100 |
Why?
| | Cell Cycle | 3 | 2006 | 632 | 0.100 |
Why?
| | Models, Biological | 1 | 2020 | 1837 | 0.100 |
Why?
| | Models, Animal | 2 | 2013 | 394 | 0.100 |
Why?
| | Male | 23 | 2024 | 72189 | 0.100 |
Why?
| | Dried Blood Spot Testing | 1 | 2013 | 126 | 0.090 |
Why?
| | Transduction, Genetic | 1 | 2013 | 138 | 0.090 |
Why?
| | Complementarity Determining Regions | 1 | 2012 | 53 | 0.090 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2021 | 950 | 0.090 |
Why?
| | Leukemia L1210 | 1 | 1992 | 7 | 0.090 |
Why?
| | Indoles | 1 | 1996 | 493 | 0.090 |
Why?
| | Islets of Langerhans Transplantation | 1 | 1992 | 70 | 0.090 |
Why?
| | Pulmonary Fibrosis | 1 | 2016 | 404 | 0.090 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 2012 | 335 | 0.090 |
Why?
| | Gene Knockdown Techniques | 1 | 2013 | 337 | 0.090 |
Why?
| | Chagas Disease | 1 | 2012 | 44 | 0.090 |
Why?
| | Middle Aged | 13 | 2024 | 35939 | 0.090 |
Why?
| | Beryllium | 2 | 2005 | 161 | 0.090 |
Why?
| | Bronchiolitis Obliterans | 1 | 2012 | 66 | 0.090 |
Why?
| | Mice, Transgenic | 3 | 2025 | 2196 | 0.090 |
Why?
| | Blood Specimen Collection | 1 | 2011 | 39 | 0.090 |
Why?
| | Interleukin Receptor Common gamma Subunit | 1 | 2011 | 14 | 0.090 |
Why?
| | Blood Banks | 1 | 2011 | 50 | 0.090 |
Why?
| | Lung | 4 | 2007 | 4190 | 0.090 |
Why?
| | Calcium | 2 | 1994 | 1184 | 0.080 |
Why?
| | Transplantation Chimera | 1 | 2011 | 57 | 0.080 |
Why?
| | Maleimides | 1 | 1991 | 21 | 0.080 |
Why?
| | International Cooperation | 1 | 2011 | 197 | 0.080 |
Why?
| | Postoperative Complications | 5 | 2017 | 2934 | 0.080 |
Why?
| | Child, Preschool | 6 | 2014 | 11740 | 0.080 |
Why?
| | Chromatography, High Pressure Liquid | 7 | 2005 | 593 | 0.080 |
Why?
| | Receptors, Transferrin | 2 | 2003 | 28 | 0.080 |
Why?
| | Mice, Knockout | 5 | 2021 | 3147 | 0.080 |
Why?
| | Colorectal Neoplasms | 1 | 2019 | 851 | 0.080 |
Why?
| | Spleen | 1 | 2013 | 518 | 0.080 |
Why?
| | Fibroblasts | 2 | 1994 | 1042 | 0.080 |
Why?
| | Serine Endopeptidases | 2 | 2022 | 128 | 0.080 |
Why?
| | Skin Tests | 1 | 2010 | 95 | 0.080 |
Why?
| | Mitogens | 2 | 1988 | 56 | 0.080 |
Why?
| | Lymph Nodes | 1 | 2013 | 505 | 0.080 |
Why?
| | Antibody Formation | 1 | 1991 | 294 | 0.080 |
Why?
| | Algorithms | 1 | 2018 | 1848 | 0.080 |
Why?
| | Siblings | 1 | 2010 | 196 | 0.080 |
Why?
| | Hematopoietic Stem Cells | 1 | 2013 | 422 | 0.080 |
Why?
| | Jurkat Cells | 2 | 2000 | 118 | 0.080 |
Why?
| | Cesarean Section | 1 | 2011 | 224 | 0.080 |
Why?
| | Genes, T-Cell Receptor beta | 2 | 2007 | 23 | 0.070 |
Why?
| | Base Sequence | 3 | 2012 | 2188 | 0.070 |
Why?
| | Nicotine | 2 | 2023 | 331 | 0.070 |
Why?
| | Genome-Wide Association Study | 1 | 2016 | 1461 | 0.070 |
Why?
| | HLA-DQ Antigens | 2 | 2000 | 173 | 0.070 |
Why?
| | Disease Susceptibility | 1 | 2011 | 352 | 0.070 |
Why?
| | Immunoglobulins, Intravenous | 3 | 1995 | 128 | 0.070 |
Why?
| | Survival Rate | 5 | 2017 | 2051 | 0.070 |
Why?
| | Cricetinae | 3 | 1994 | 300 | 0.070 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1967 | 0.070 |
Why?
| | Cell Survival | 3 | 1997 | 1113 | 0.070 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2016 | 697 | 0.070 |
Why?
| | Lung Transplantation | 1 | 2012 | 336 | 0.070 |
Why?
| | Phytohemagglutinins | 4 | 1991 | 29 | 0.070 |
Why?
| | Allografts | 2 | 2019 | 151 | 0.070 |
Why?
| | Adolescent | 7 | 2014 | 22396 | 0.070 |
Why?
| | Research Design | 1 | 2014 | 1128 | 0.070 |
Why?
| | Anemia, Sickle Cell | 1 | 2012 | 309 | 0.070 |
Why?
| | Molecular Sequence Data | 3 | 2012 | 2914 | 0.070 |
Why?
| | Genetic Linkage | 2 | 2006 | 274 | 0.070 |
Why?
| | Amino Acids | 1 | 2011 | 520 | 0.070 |
Why?
| | Mice, Nude | 2 | 2020 | 692 | 0.070 |
Why?
| | Mice, Inbred NOD | 2 | 2021 | 618 | 0.070 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2020 | 219 | 0.060 |
Why?
| | Isoantigens | 1 | 1987 | 17 | 0.060 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2019 | 949 | 0.060 |
Why?
| | Cell Differentiation | 4 | 2021 | 2060 | 0.060 |
Why?
| | Transcription Factor AP-1 | 1 | 2007 | 79 | 0.060 |
Why?
| | NFATC Transcription Factors | 1 | 2007 | 93 | 0.060 |
Why?
| | Cloning, Molecular | 2 | 1998 | 543 | 0.060 |
Why?
| | Kidney Function Tests | 2 | 2017 | 158 | 0.060 |
Why?
| | Aged | 6 | 2024 | 25822 | 0.060 |
Why?
| | Follow-Up Studies | 5 | 2018 | 5350 | 0.060 |
Why?
| | Aldehydes | 1 | 2007 | 144 | 0.060 |
Why?
| | HLA-B15 Antigen | 1 | 2006 | 11 | 0.060 |
Why?
| | Enzyme Induction | 1 | 2006 | 87 | 0.060 |
Why?
| | Muromonab-CD3 | 2 | 1997 | 6 | 0.060 |
Why?
| | Sequence Homology | 1 | 2006 | 44 | 0.060 |
Why?
| | Lung Diseases | 2 | 2006 | 796 | 0.060 |
Why?
| | Butylated Hydroxytoluene | 1 | 2006 | 36 | 0.060 |
Why?
| | Bone Marrow | 2 | 2021 | 303 | 0.060 |
Why?
| | Prognosis | 4 | 2017 | 4253 | 0.060 |
Why?
| | Microspheres | 1 | 2006 | 141 | 0.060 |
Why?
| | HLA-DP Antigens | 1 | 2005 | 32 | 0.060 |
Why?
| | Cysteine | 1 | 2007 | 211 | 0.060 |
Why?
| | Autoantigens | 2 | 2021 | 432 | 0.060 |
Why?
| | Phospholipases A | 1 | 2006 | 102 | 0.060 |
Why?
| | Phenotype | 3 | 2021 | 3199 | 0.060 |
Why?
| | Arginine | 1 | 2007 | 267 | 0.060 |
Why?
| | Biliary Atresia | 1 | 2007 | 145 | 0.060 |
Why?
| | Cell Proliferation | 2 | 2020 | 2543 | 0.060 |
Why?
| | Transfection | 2 | 1998 | 952 | 0.060 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2005 | 131 | 0.060 |
Why?
| | Phenols | 1 | 2006 | 115 | 0.060 |
Why?
| | Neoplasms | 1 | 2021 | 2929 | 0.060 |
Why?
| | Child | 5 | 2014 | 22620 | 0.060 |
Why?
| | Arteriosclerosis | 1 | 2005 | 83 | 0.050 |
Why?
| | NAD(P)H Dehydrogenase (Quinone) | 1 | 2004 | 35 | 0.050 |
Why?
| | Chemokines, CXC | 1 | 2004 | 70 | 0.050 |
Why?
| | Treatment Outcome | 5 | 2024 | 11581 | 0.050 |
Why?
| | Acetylcysteine | 1 | 2005 | 141 | 0.050 |
Why?
| | Antigen Presentation | 1 | 2005 | 216 | 0.050 |
Why?
| | Skin Transplantation | 1 | 2025 | 86 | 0.050 |
Why?
| | Structure-Activity Relationship | 3 | 1991 | 569 | 0.050 |
Why?
| | Reoperation | 3 | 1998 | 614 | 0.050 |
Why?
| | Amino Acid Substitution | 1 | 2025 | 304 | 0.050 |
Why?
| | Agglutination | 2 | 1997 | 5 | 0.050 |
Why?
| | Case-Control Studies | 1 | 2011 | 3628 | 0.050 |
Why?
| | Young Adult | 3 | 2024 | 14033 | 0.050 |
Why?
| | Pandemics | 2 | 2024 | 1685 | 0.050 |
Why?
| | Bone Marrow Transplantation | 1 | 2025 | 294 | 0.050 |
Why?
| | Surveys and Questionnaires | 1 | 2016 | 6052 | 0.050 |
Why?
| | Antigens, Differentiation, B-Lymphocyte | 1 | 2003 | 37 | 0.050 |
Why?
| | Concanavalin A | 3 | 1988 | 71 | 0.050 |
Why?
| | Berylliosis | 1 | 2005 | 202 | 0.050 |
Why?
| | Lectins, C-Type | 1 | 2003 | 63 | 0.050 |
Why?
| | E2F Transcription Factors | 1 | 2003 | 76 | 0.050 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 2003 | 102 | 0.050 |
Why?
| | Glomerular Filtration Rate | 2 | 2017 | 753 | 0.050 |
Why?
| | Polymorphism, Genetic | 1 | 2006 | 620 | 0.050 |
Why?
| | Mesocricetus | 2 | 1992 | 46 | 0.050 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2004 | 382 | 0.050 |
Why?
| | Immunophenotyping | 2 | 2015 | 327 | 0.050 |
Why?
| | Risk Factors | 6 | 2017 | 10672 | 0.050 |
Why?
| | Cell Line, Transformed | 2 | 1992 | 141 | 0.050 |
Why?
| | Respiratory Tract Infections | 1 | 2007 | 397 | 0.050 |
Why?
| | Superoxide Dismutase | 1 | 2004 | 351 | 0.050 |
Why?
| | Phosphoproteins | 1 | 2005 | 348 | 0.050 |
Why?
| | Severity of Illness Index | 1 | 2010 | 2940 | 0.050 |
Why?
| | Biomarkers | 2 | 2019 | 4279 | 0.050 |
Why?
| | Drug Synergism | 2 | 1996 | 364 | 0.040 |
Why?
| | Cell Communication | 2 | 2013 | 326 | 0.040 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 1987 | 179 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2003 | 170 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2005 | 649 | 0.040 |
Why?
| | Cyclophosphamide | 1 | 2022 | 270 | 0.040 |
Why?
| | Apoptosis | 2 | 2020 | 2454 | 0.040 |
Why?
| | T-Lymphocyte Subsets | 2 | 2016 | 422 | 0.040 |
Why?
| | Neutrophils | 2 | 2005 | 1146 | 0.040 |
Why?
| | Chimerism | 1 | 2021 | 35 | 0.040 |
Why?
| | Leukemia | 2 | 2012 | 248 | 0.040 |
Why?
| | Iron Chelating Agents | 1 | 2000 | 18 | 0.040 |
Why?
| | Antioxidants | 2 | 2006 | 581 | 0.040 |
Why?
| | Biopsy | 2 | 2019 | 1071 | 0.040 |
Why?
| | Lymphocyte Subsets | 1 | 2021 | 87 | 0.040 |
Why?
| | Cell Separation | 2 | 2011 | 312 | 0.040 |
Why?
| | Antibody Specificity | 1 | 2001 | 185 | 0.040 |
Why?
| | Ganglionic Stimulants | 1 | 2000 | 15 | 0.040 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2023 | 392 | 0.040 |
Why?
| | Lymphoid Tissue | 1 | 2021 | 80 | 0.040 |
Why?
| | Kidney | 4 | 2019 | 1496 | 0.040 |
Why?
| | Virus Internalization | 1 | 2020 | 66 | 0.040 |
Why?
| | Leukocyte Elastase | 1 | 2020 | 76 | 0.040 |
Why?
| | Free Radicals | 1 | 2000 | 107 | 0.040 |
Why?
| | Dimerization | 1 | 2000 | 194 | 0.040 |
Why?
| | RNA | 2 | 1997 | 941 | 0.040 |
Why?
| | Blotting, Western | 2 | 2004 | 1207 | 0.040 |
Why?
| | Extracellular Traps | 1 | 2020 | 58 | 0.040 |
Why?
| | Gene Expression | 1 | 2005 | 1517 | 0.040 |
Why?
| | Ligands | 1 | 2022 | 674 | 0.040 |
Why?
| | Biological Evolution | 1 | 2024 | 489 | 0.040 |
Why?
| | Antithrombins | 1 | 2020 | 70 | 0.040 |
Why?
| | Mice, SCID | 1 | 2021 | 377 | 0.040 |
Why?
| | Tyrosine | 1 | 2000 | 227 | 0.040 |
Why?
| | Nephelometry and Turbidimetry | 2 | 2013 | 15 | 0.040 |
Why?
| | Antigens, CD | 1 | 2003 | 564 | 0.040 |
Why?
| | Arthroplasty, Replacement | 1 | 2020 | 47 | 0.040 |
Why?
| | Luminescent Measurements | 2 | 2013 | 76 | 0.040 |
Why?
| | Bone Marrow Cells | 1 | 2021 | 321 | 0.040 |
Why?
| | Granuloma, Respiratory Tract | 1 | 1999 | 13 | 0.040 |
Why?
| | Inflammation | 3 | 2006 | 2911 | 0.040 |
Why?
| | Receptors, Cytokine | 1 | 1999 | 36 | 0.040 |
Why?
| | Cytokines | 1 | 2007 | 2100 | 0.040 |
Why?
| | Xenobiotics | 1 | 1999 | 33 | 0.040 |
Why?
| | Steroid 21-Hydroxylase | 1 | 1999 | 27 | 0.040 |
Why?
| | Receptors, Interferon | 1 | 1999 | 60 | 0.040 |
Why?
| | Addison Disease | 1 | 1999 | 39 | 0.040 |
Why?
| | Viral Tropism | 1 | 2018 | 36 | 0.040 |
Why?
| | Antigens, CD34 | 2 | 2013 | 88 | 0.040 |
Why?
| | Metallothionein | 1 | 1998 | 25 | 0.030 |
Why?
| | Immunoglobulin M | 2 | 1991 | 288 | 0.030 |
Why?
| | Antibodies, Monoclonal | 3 | 1991 | 1524 | 0.030 |
Why?
| | Virus Latency | 1 | 2018 | 90 | 0.030 |
Why?
| | Virus Activation | 1 | 2018 | 95 | 0.030 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 162 | 0.030 |
Why?
| | Genotyping Techniques | 1 | 2018 | 70 | 0.030 |
Why?
| | Pokeweed Mitogens | 2 | 1988 | 7 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 2 | 2012 | 580 | 0.030 |
Why?
| | Depression, Chemical | 1 | 1997 | 16 | 0.030 |
Why?
| | Mycophenolic Acid | 1 | 1998 | 120 | 0.030 |
Why?
| | Drug Therapy, Combination | 2 | 1998 | 1033 | 0.030 |
Why?
| | Lymphocyte Function-Associated Antigen-1 | 1 | 1997 | 27 | 0.030 |
Why?
| | 3T3 Cells | 1 | 1997 | 159 | 0.030 |
Why?
| | Acute Lung Injury | 1 | 2020 | 308 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2005 | 2860 | 0.030 |
Why?
| | Insulin, Long-Acting | 1 | 1997 | 65 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2020 | 483 | 0.030 |
Why?
| | New York | 1 | 1997 | 125 | 0.030 |
Why?
| | Sulfhydryl Compounds | 2 | 1991 | 189 | 0.030 |
Why?
| | Guanidines | 1 | 1996 | 41 | 0.030 |
Why?
| | Contraindications | 1 | 2016 | 84 | 0.030 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 1997 | 140 | 0.030 |
Why?
| | Complement Activation | 1 | 2019 | 412 | 0.030 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2016 | 46 | 0.030 |
Why?
| | S Phase | 1 | 1996 | 88 | 0.030 |
Why?
| | Immunoglobulin lambda-Chains | 1 | 2015 | 9 | 0.030 |
Why?
| | Costs and Cost Analysis | 1 | 1997 | 215 | 0.030 |
Why?
| | Half-Life | 2 | 1996 | 150 | 0.030 |
Why?
| | Immunoglobulin kappa-Chains | 1 | 2015 | 23 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2021 | 6406 | 0.030 |
Why?
| | Linkage Disequilibrium | 1 | 2016 | 249 | 0.030 |
Why?
| | Liver | 3 | 2007 | 1853 | 0.030 |
Why?
| | Desensitization, Immunologic | 1 | 2016 | 95 | 0.030 |
Why?
| | B-Lymphocyte Subsets | 1 | 2015 | 80 | 0.030 |
Why?
| | Cross Reactions | 3 | 1990 | 135 | 0.030 |
Why?
| | Antigens, Viral, Tumor | 1 | 1994 | 8 | 0.030 |
Why?
| | Antigens, CD19 | 1 | 2015 | 139 | 0.030 |
Why?
| | Genetic Loci | 1 | 2016 | 275 | 0.030 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 1994 | 153 | 0.030 |
Why?
| | Iron | 1 | 1997 | 357 | 0.030 |
Why?
| | Transplant Recipients | 1 | 2016 | 180 | 0.030 |
Why?
| | Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 2 | 2007 | 27 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2001 | 1379 | 0.030 |
Why?
| | Mortality | 1 | 2016 | 364 | 0.030 |
Why?
| | Prevalence | 1 | 2001 | 2830 | 0.030 |
Why?
| | Mice, Inbred DBA | 2 | 1992 | 188 | 0.030 |
Why?
| | Thioguanine | 1 | 2013 | 18 | 0.020 |
Why?
| | Cell Adhesion | 1 | 1994 | 457 | 0.020 |
Why?
| | Immunization, Passive | 1 | 1993 | 87 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2013 | 169 | 0.020 |
Why?
| | Umbilical Cord | 1 | 2013 | 92 | 0.020 |
Why?
| | Survivors | 1 | 2016 | 515 | 0.020 |
Why?
| | Lymphocyte Depletion | 1 | 2013 | 135 | 0.020 |
Why?
| | Drug Resistance | 1 | 2013 | 154 | 0.020 |
Why?
| | Adoptive Transfer | 1 | 2013 | 220 | 0.020 |
Why?
| | Survival Analysis | 2 | 2012 | 1362 | 0.020 |
Why?
| | Myeloid Cells | 1 | 2013 | 148 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2024 | 8185 | 0.020 |
Why?
| | Mercaptopurine | 1 | 1991 | 15 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2012 | 174 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2019 | 2186 | 0.020 |
Why?
| | Mice, Inbred C57BL | 3 | 2011 | 6067 | 0.020 |
Why?
| | Anticoagulants | 1 | 2016 | 721 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2019 | 3633 | 0.020 |
Why?
| | Lymphoma | 1 | 2012 | 235 | 0.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2006 | 650 | 0.020 |
Why?
| | Signal Transduction | 2 | 2021 | 5277 | 0.020 |
Why?
| | Blood Donors | 1 | 2011 | 143 | 0.020 |
Why?
| | Glucose | 1 | 1994 | 1048 | 0.020 |
Why?
| | Methylmannosides | 1 | 1989 | 1 | 0.020 |
Why?
| | Cytochalasins | 1 | 1989 | 3 | 0.020 |
Why?
| | Rosette Formation | 1 | 1989 | 14 | 0.020 |
Why?
| | Colchicine | 1 | 1989 | 21 | 0.020 |
Why?
| | Preoperative Care | 1 | 2012 | 379 | 0.020 |
Why?
| | Fetus | 1 | 2013 | 803 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1829 | 0.020 |
Why?
| | Monocytes | 2 | 1989 | 544 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2013 | 1987 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2011 | 904 | 0.020 |
Why?
| | Immunotherapy, Adoptive | 1 | 1992 | 389 | 0.020 |
Why?
| | Bile Ducts, Extrahepatic | 1 | 2007 | 20 | 0.020 |
Why?
| | Lipid Peroxides | 1 | 1987 | 10 | 0.020 |
Why?
| | Oligoclonal Bands | 1 | 2007 | 26 | 0.020 |
Why?
| | Interleukin-6 | 1 | 1991 | 791 | 0.020 |
Why?
| | Blood Glucose | 1 | 1997 | 2335 | 0.020 |
Why?
| | DNA Replication | 1 | 1989 | 259 | 0.020 |
Why?
| | Evaluation Studies as Topic | 1 | 1987 | 169 | 0.020 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2006 | 37 | 0.020 |
Why?
| | Chemokine CCL8 | 1 | 2006 | 3 | 0.020 |
Why?
| | Monocyte Chemoattractant Proteins | 1 | 2006 | 8 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2012 | 2103 | 0.010 |
Why?
| | Phospholipases A2 | 1 | 2006 | 82 | 0.010 |
Why?
| | Chemokine CCL2 | 1 | 2006 | 115 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2013 | 3411 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2005 | 278 | 0.010 |
Why?
| | Age Factors | 1 | 2013 | 3311 | 0.010 |
Why?
| | NADPH Dehydrogenase | 1 | 2005 | 6 | 0.010 |
Why?
| | Cytosol | 1 | 2006 | 227 | 0.010 |
Why?
| | NADH Dehydrogenase | 1 | 2005 | 20 | 0.010 |
Why?
| | Immunity, Cellular | 1 | 1987 | 273 | 0.010 |
Why?
| | Chemokine CXCL1 | 1 | 2004 | 76 | 0.010 |
Why?
| | Monitoring, Physiologic | 1 | 1987 | 291 | 0.010 |
Why?
| | Infant | 3 | 2007 | 9987 | 0.010 |
Why?
| | Translocation, Genetic | 1 | 2005 | 115 | 0.010 |
Why?
| | NADPH Oxidases | 1 | 2005 | 130 | 0.010 |
Why?
| | Leukemia, Lymphoid | 1 | 1983 | 27 | 0.010 |
Why?
| | Mice, Inbred AKR | 1 | 1983 | 37 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 1988 | 1099 | 0.010 |
Why?
| | Leukemia, Experimental | 1 | 1983 | 28 | 0.010 |
Why?
| | Lymphokines | 1 | 1983 | 130 | 0.010 |
Why?
| | Blood Transfusion | 1 | 1987 | 405 | 0.010 |
Why?
| | Acute Disease | 1 | 2006 | 1006 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2004 | 783 | 0.010 |
Why?
| | Necrosis | 1 | 1984 | 245 | 0.010 |
Why?
| | Kinetics | 1 | 1986 | 1627 | 0.010 |
Why?
| | Rats | 3 | 2004 | 5632 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2006 | 1504 | 0.010 |
Why?
| | Cohort Studies | 1 | 2012 | 5898 | 0.010 |
Why?
| | Leukocyte Count | 1 | 2002 | 319 | 0.010 |
Why?
| | HLA-DQ alpha-Chains | 1 | 2000 | 16 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 1991 | 1913 | 0.010 |
Why?
| | Genes, T-Cell Receptor alpha | 1 | 1999 | 12 | 0.010 |
Why?
| | Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 1 | 1999 | 21 | 0.010 |
Why?
| | Hematologic Neoplasms | 1 | 2002 | 162 | 0.010 |
Why?
| | Cell Culture Techniques | 1 | 2002 | 380 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2004 | 2538 | 0.010 |
Why?
| | Clone Cells | 1 | 1999 | 269 | 0.010 |
Why?
| | United States | 1 | 2016 | 15723 | 0.010 |
Why?
| | Prospective Studies | 3 | 1996 | 7947 | 0.010 |
Why?
| | Pregnancy | 1 | 2011 | 7197 | 0.010 |
Why?
| | Azathioprine | 1 | 1998 | 48 | 0.010 |
Why?
| | Incidence | 2 | 1995 | 2865 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2002 | 1086 | 0.010 |
Why?
| | Prednisone | 1 | 1998 | 224 | 0.010 |
Why?
| | Infusions, Intra-Arterial | 1 | 1996 | 62 | 0.010 |
Why?
| | Risk Assessment | 1 | 2006 | 3580 | 0.010 |
Why?
| | Metabolic Clearance Rate | 1 | 1996 | 116 | 0.010 |
Why?
| | Injections, Intravenous | 1 | 1996 | 200 | 0.010 |
Why?
| | Risk | 1 | 1999 | 905 | 0.010 |
Why?
| | Transplantation, Autologous | 1 | 1996 | 292 | 0.010 |
Why?
| | Blood Group Incompatibility | 1 | 1995 | 20 | 0.010 |
Why?
| | Dogs | 1 | 1996 | 438 | 0.010 |
Why?
| | Species Specificity | 2 | 1988 | 576 | 0.010 |
Why?
| | Cytomegalovirus | 1 | 1995 | 168 | 0.010 |
Why?
| | Diabetic Nephropathies | 1 | 1998 | 313 | 0.010 |
Why?
| | ABO Blood-Group System | 1 | 1995 | 58 | 0.010 |
Why?
| | Cadaver | 1 | 1995 | 302 | 0.010 |
Why?
| | Infusions, Intravenous | 1 | 1994 | 427 | 0.010 |
Why?
| | Drug Costs | 1 | 1994 | 114 | 0.010 |
Why?
| | Antibodies, Viral | 1 | 1995 | 686 | 0.010 |
Why?
| | Breast Neoplasms | 1 | 2002 | 2517 | 0.000 |
Why?
| | Rats, Inbred SHR | 1 | 1988 | 38 | 0.000 |
Why?
| | Deferoxamine | 1 | 1988 | 25 | 0.000 |
Why?
| | Malondialdehyde | 1 | 1988 | 30 | 0.000 |
Why?
| | Biotransformation | 1 | 1988 | 62 | 0.000 |
Why?
| | Length of Stay | 1 | 1994 | 1321 | 0.000 |
Why?
| | Injections, Subcutaneous | 1 | 1988 | 166 | 0.000 |
Why?
| | Tissue Distribution | 1 | 1988 | 328 | 0.000 |
Why?
| | Kidney Cortex | 1 | 1986 | 27 | 0.000 |
Why?
| | Kidney Medulla | 1 | 1986 | 31 | 0.000 |
Why?
| | Administration, Oral | 1 | 1988 | 844 | 0.000 |
Why?
| | Blood Physiological Phenomena | 1 | 1983 | 12 | 0.000 |
Why?
| | Suppressor Factors, Immunologic | 1 | 1983 | 4 | 0.000 |
Why?
| | Mice, Inbred CBA | 1 | 1983 | 58 | 0.000 |
Why?
| | Thymidine | 1 | 1983 | 59 | 0.000 |
Why?
| | Kidney Diseases | 1 | 1988 | 421 | 0.000 |
Why?
| | Rats, Inbred Strains | 1 | 1983 | 321 | 0.000 |
Why?
|
|
Freed's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|